The Cost Implication of Trastuzumab in Patients With HER2-Positive Breast Cancer at Moi Teaching and Referal Hospital, Eldoret, Kenya

A year course of trastuzumab revolutionized treatment for human epidermal growth factor receptor (HER2)-positive breast cancer by increasing survival rates. However, trastuzumab treatment is cost-prohibitive, and data on abbreviated courses is lacking in advanced disease. At Moi Teaching and Referra...

Descripción completa

Detalles Bibliográficos
Autores principales: Wabende, Lucy Najala, Bhatia, Manisha, Kiptoo, Stephen, Kisilu, Nicholas, Kiboss, Caroline, Kibiwot, Silvanus, Jepkirui, Sally, Awuor, Dorice Adhiambo, Busakhala, Naftali, Hunter-Squires, Joanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
MEETING PROCEEDINGS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9906546/
http://dx.doi.org/10.1200/GO.22.54000

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9906546/
http://dx.doi.org/10.1200/GO.22.54000

Ejemplares similares